首页> 外文期刊>Health technology assessment: HTA >The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.
【24h】

The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

机译:的有效性和成本效益最小的手术患者之间的访问gastro-oesophageal返流性疾病——英国协作学习。

获取原文
       

摘要

OBJECTIVES: To evaluate the clinical effectiveness, cost-effectiveness and safety of a policy of relatively early laparoscopic surgery compared with continued medical management amongst people with gastro-oesophageal reflux disease (GORD) judged suitable for both policies. DESIGN: Relative clinical effectiveness was assessed by a randomised trial (with parallel non-randomised preference groups) comparing a laparoscopic surgery-based policy with a continued medical management policy. The economic evaluation compared the cost-effectiveness of the two management policies in order to identify the most efficient provision of future care and describe the resource impact that various policies for fundoplication would have on the NHS. SETTING: A total of 21 hospitals throughout the UK with a local partnership between surgeon(s) and gastroenterologist(s) who shared the secondary care of patients with GORD. PARTICIPANTS: The 810 participants, who were identified retrospectively or prospectively via their participating clinicians, had both documented evidence of GORD (endoscopy and/or manometry/24-hour pH monitoring) and symptoms for longer than 12 months. In addition, the recruiting clinician(s) was clinically uncertain about which management policy was best. INTERVENTION: Of the 810 eligible patients who consented to participate, 357 were recruited to the randomised arm of the trial (178 allocated to surgical management, 179 allocated to continued, but optimised, medical management) and 453 recruited to the parallel non-randomised preference arm (261 chose surgical management, 192 chose to continue with best medical management). The type of fundoplication was left to the discretion of the surgeon. MAIN OUTCOME MEASURES: Participants completed a baseline REFLUX questionnaire, developed specifically for this study, containing a disease-specific outcome measure, the Short Form with 36 Items (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Beliefs about Medicines and Surgery questionnaires (BMQ/BSQ). Postal questionnaires were completed at participant-specific time intervals after joining the trial (equivalent to approximately 3 and 12 months after surgery). Intraoperative data were recorded by the surgeons and all other in-hospital data were collected by the research nurse. At the end of the study period, participants completed a discrete choice experiment questionnaire. RESULTS: The randomised groups were well balanced at entry. Participants had been taking GORD medication for a median of 32 months; the mean age of participants was 46 years and 66% were men. Of 178 randomised to surgery, 111 (62%) actually had fundoplication. There was a mixture of clinical and personal reasons why some patients did not have surgery, sometimes related to long waiting times. A total or partial wrap procedure was performed depending on surgeon preference. Complications were uncommon and there were no deaths associated with surgery. By the equivalent of 12 months after surgery, 38% in the randomised surgical group (14% amongst those who had surgery) were taking reflux medication compared with 90% in the randomised medical group. There were substantial differences (one-third to one-half standard deviation) favouring the randomised surgical group across the health status measures, the size depending on assumptions about the proportion that actually had fundoplication. These differences were the same or somewhat smaller than differences observed at 3 months. The lower the REFLUX score, the worse the symptoms at trial entry and the larger the benefit observed after surgery. The preference surgical group had the lowest REFLUX scores at baseline. These scores improved substantially after surgery, and by 12 months they were better than those in the preference medical group. The BMQ/BSQ and discrete choice experiment did distinguish the preference groups from each other and from the randomised groups. The latter indicated that the risk of serious complications was
机译:目的:评价临床效率、成本效益和安全的政策的相对早期的腹腔镜手术而持续的医疗管理在患者gastro-oesophageal反胃疾病(GORD)判断适合这两项政策。设计:相对的临床效果评估一个随机试验(平行non-randomised偏好组)进行比较腹腔镜surgery-based政策了持续的医疗管理政策。评估的成本效益比两个管理政策,以便识别最有效的提供护理和未来描述了各种资源的影响fundoplication政策上NHS。英国与当地伙伴关系外科医生(s)和胃肠病学家(s)共享二级护理的GORD患者。参与者:810名参与者,他们回顾性分析或通过前瞻性他们的参与的临床医生,都记录的GORD(内镜和/或证据测压法/ pH值24小时监控)和症状超过12个月。招聘临床医生(s)是临床上不确定哪些管理政策是最好的。干预:810年符合条件的患者同意参与,357被招募随机的试验(178分配手术治疗,179年分配给继续说道,但优化、医疗管理)和453年招募并行non-randomised偏好的手臂(261选择手术治疗,192年最好选择继续医疗管理)。自由裁量权的外科医生。措施:参与者完成了一个基准回流问卷,专门为开发这项研究中,包含一个特定疾病的结果措施,短形式的36项(SF-36),EuroQol-5维度(EQ-5D)和信仰关于药物和手术的调查问卷(BMQ / BSQ)。在participant-specific时间间隔加入试验(相当于约3和手术后12个月)。由外科医生和所有其他记录吗住院数据收集的研究护士。参与者完成一个离散的选择实验调查问卷。组均衡的条目。一直服用GORD药物中位数的32个月;年,66%都是男性。手术,111例(62%)有fundoplication。有临床和个人的混合物为什么有些病人没有手术,有时长等待时间有关。根据执行或部分包装程序外科医生的偏好。罕见,没有死亡手术。随机的外科手术,38%组(14%在那些手术)回流药物的比例为90%随机医疗集团。差异(标准的三分之一到一半偏差)支持随机手术集团在健康状况的措施,大小对比例取决于假设实际上fundoplication。差异是相同的或比较小比差异观察到3个月。回流的分数,最严重的症状在审判入口和受益越大观察后手术。最低回流分数在基线。大幅改进的手术后,12个月比他们更好医疗集团的偏好。离散选择试验做了区分从彼此和偏好组随机群体。严重并发症的风险

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号